1. Scrip

O'Neill: UK 'Lost Focus' On Antibiotic Crisis And Pharma Must Do More

 
• By Kevin Grogan

The time for talking is over when it comes to antimicrobial resistance, says Jim O'Neill, urging the government to 'rediscover the passion for championing' initiatives in the UK, notably the new AMR Centre in Alderley Park near Manchester.

CRUK Manchester Institute
New home: Alderley Park chief Chris Doherty and CRUK's Richard Marais (r) • Source: MSP

As the threat of a dwindling supply of effective antibiotics grows, one of the most prominent people involved in tackling the issue – Lord (Jim) O'Neill – fears that 2017 has seen research in the field lag even further behind.

O’Neill, a former Goldman Sachs chief economist, ex-Treasury minister and author of a landmark review commissioned by David Cameron when he was prime minister on antimicrobial resistance (AMR), said this week that the UK government has "lost focus" on the challenge

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

More from Therapy Areas

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.